

# RPRD1B

PDB:4FLD

## Revision

**Revision Type:**created

**Revised by:**created

**Revision Date:**created

**Entry Clone Accession:**NP\_067038.1

**Entry Clone Source:**MGC DNA 05-F5 (NP\_067038.1)

**SGC Clone Accession:**RPRD1B (DCC020G07): 2-135

**Tag:**TagN-terminal tag: MHHHHHHSSGRENLYFQG

**Host:**BL21 (DE3) Codon plus RIL (Stratagene)

## Construct

**Prelude:**

**Sequence:**

MHHHHHHSSGRENLYFQG SSFSESALKKLSLSNSQQSVQTLWLIIHRKHAGPIVSVWHRELKAKSNRKLTFLYLANDVIQN  
SKRKGPEFTREFESVLVDAFSHVAREADEGCKKPLERLLNIWQERSVYGGEFIQQLKLSMEDSKSP

**Vector:**pET15-MHL

## Growth

**Medium:**

**Antibiotics:**

**Procedure:**A 250 mL flask containing LB (Sigma L7658) supplemented with 50 µg/mL kanamycin (BioShop Canada KAN 201) was inoculated from a glycerol stock of the bacteria. The flask was shaken overnight (16 hours) at 250 rpm at 37 °C. Using the Lex system, a 2L bottle (VWR 89000-242) containing 1800 mL of TB (Sigma T0918) supplemented with 1.5% glycerol, 50 µg/ mL kanamycin and 600 µl antifoam 204 (Sigma A-8311) was inoculated with 50 mL overnight LB culture, and incubated at 37 °C. The temperature of the media was reduced to 15 °C one hour prior to induction and induced at OD600 = 6 with 100 µM isopropyl-thio-β-D-galactopyranoside (BioShop Canada IPT 001). Cultures were aerated overnight (16 hours) at 15 °C, and cell pellets collected by centrifugation and frozen at -80 °C.

## Purification

### Procedure

IMAC: Unclearified lysate was mixed with 2-3 mL of Ni-NTA superflow Resin (Qiagen) per 40 mL lysate. The mixture was incubated with mixing for at least 45 minutes at 4°C. The mixture was then loaded onto an empty comLum (BioRad) and washed with 100 mL wash buffer. Samples were eluted from the resin by exposure to 2-3 column volumes (approx. 10-15 mL) of elution buffer. Concentration of eluted protein was estimated by OD280. pTEV was added to eluted protein at 1:20 for eluted protein and dialyze against gel filtration buffer overnight to remove His-tag.

Gel filtration chromatography: An XK 26x65 column (GE Healthcare) packed with HighLoad Superdex 75 resin (GE Healthcare) was pre-equilibrated with gel filtration buffer for 1.5 column volumes using an AKTA explorer (GE Healthcare) at a flow rate of 1.0 mL/min. The dialyzed sample from the IMAC step (approx. 15 mL) was loaded onto the column at 1.5 mL/min, and 2mL fractions were collected into 96-well plates (VWR 40002-012) using peak fractionation protocols). Fractions observed by a UV absorption chromatogram to contain the protein were pooled.

## Extraction

### Procedure

Frozen cell pellet contained in bags (Beckman 369256) obtained from 2L of culture were thawed by soaking in warm water. Each cell pellet was resuspended in 25-40 mL lysis buffer and homogenized using an Ultra-Turrax T8 homogenizer (IKA Works) at maximal setting for 30-60 seconds per pellet. Cell lysis was accomplished by sonication (Virtis408912, Virsonic) on ice: the sonication protocol was 10 sec pulse at half-maximal frequency (5.0), 10 second rest, for 10 minutes total sonication time per pellet.

**Concentration:** Purified proteins were concentrated using 15 mL concentrators with a 5,000 molecular weight cut-off (Amicon Ultra-15, UFC900524, Millipore) at 3750 rpm, typically resulting in a final concentration around 30 mg/mL.

### Ligand

#### MassSpec:

**Crystallization:** The apo RPRD1B CID domain was crystallized in a buffer containing 30% PEG550MME, 0.1M ammonium sulfate, 0.1M sodium cacodylate, pH 6.5; The RPRD1B was mixed with unmodified or phosphorylated Ser2 CTD in a ratio of 1:3 and put on ice for 30 minutes before crystallization. The RPRD1B- S2P complex was crystallized in a buffer containing 2.0 M ammonium sulfate, 5% isopropanol. The RPRD1B- unCTD complex was crystallized in a buffer containing 25% PEG-1500, 0.2M ammonium sulfate, 0.1M HEPES, pH 7.5. The crystals were soaked in a cryoprotectant consisting of 88% reservoir solution and 12% glycerol (v/v).

#### NMR Spectroscopy:

**Data Collection:**  
**Data Processing:**